Abbott Aims To Get Nutritionals Back On Track In Wake Of Similac Recall
This article was originally published in The Tan Sheet
Executive Summary
Abbott says its nutrition business is on track for a return to full-scale production and growth after absorbing an expected $100 million hit to third-quarter sales from its September Similac recall